Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 17136 Insp GMP/IMP 17136/2431088-0009[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER*(1),(2)*

Part 1

Issued following an inspection in accordance with :
Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : NEWCASTLE ADVANCED THERAPIES CFL

Site address : NEWCASTLE ADVANCED THERAPIES CFL, BIOSCIENCE CENTRE, INTERNATIONAL CENTRE FOR LIFE, TIMES SQUARE, NEWCASTLE UPON TYNE, NE1 3BZ, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 17136 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 25/08/2026 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- *(1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.*
- *(2) These requirements fulfil the GMP recommendations of WHO.*

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.6] Other aseptically prepared products
Cellular therapies, tissue engineered products

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.3] Cell therapy products

[1.3.1.8] Other biological medicinal products

Tissue Engineered Products

[1.4] Other products or manufacturing activity

[1.4.1] Manufacture of:

[1.4.1.3] Other

Quality Control Testing - Microbiological: non-sterility restricted to Gram Stain

[1.5] Packaging

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.2] Microbiological: non-sterility

[1.6.3] Chemical/Physical

[1.6.4] Biological

Any restrictions related to the scope of this certificate:

Building	Room	Line/equipment	QC Testing	Products
Facilities in Framlington Place and Times Square were both inspected.			Chemical/physical, biological and microbiological (most work is contracted out).	Biologicals including cellular therapies - ATMP site

06/11/2026	Name and signature of the authorised person of the Competent Authority of United Kingdom Confidential Medicines and Healthcare products Regulatory Agency Tel : Confidential

MHRA-GMDP MHRA